<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Exelixis Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/exelixis-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AKRX) Company News for June 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683</link>
		<comments>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683#comments</comments>
		<pubDate>Tue, 07 Jun 2011 16:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Akorn Inc]]></category>
		<category><![CDATA[AKRX]]></category>
		<category><![CDATA[AMED]]></category>
		<category><![CDATA[Amedisys Inc.]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LOW]]></category>
		<category><![CDATA[Lowe's Companies Inc.]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75683</guid>
		<description><![CDATA[•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 •    According to Canaccord Genuity, data from a trial of Exelixis, Inc&#8217;s (NASDAQ:EXEL) cancer-drug candidate could possibly worsen its regulatory strategy •    According to the Wall Street Journal, Novartis AG (NYSE:NVS) could possibly opt out from the buying race for medical test manufacturer Gen-Probe Inc (NASDAQ:GPRO) •    Merge Healthcare Inc (NASDAQ:MRGE) announced plans to buy Ophthalmic Imaging Systems (OTC:OISI) for a deal worth $30.3 million in stock •    U.S.-listed shares of Peruvian metal producer Southern Copper Corp. (NYSE:SCCO) declined 11.35%, after a former army rebel won Peru&#8217;s presidential elections •    Raymond James Financial Inc. downgraded Credicorp Ltd (NYSE:BAP) , the Peruvian financial-services firm from &#8220;Outperform&#8221; to &#8220;Underperform&#8221; rating •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen</title>
		<link>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058</link>
		<comments>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058#comments</comments>
		<pubDate>Thu, 01 Jul 2010 16:50:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42058</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company, is focused on the development of candidates for the treatment of certain types of leukemia, lymphoma and other hematological malignancies and blood disorders. Deal Could be Worth $560M Per the terms of the agreement, TargaGen will receive $75 million once the transaction closes. Sanofi will make additional payments on the achievement of development milestones. Including the $75 million upfront payment, Sanofi could end up paying up to $560 million. The deal is scheduled to close in the third quarter of 2010. Deal to Expand Oncology Pipeline TargaGen’s lead pipeline candidate, TG101348, is an oral agent that is being developed for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EXEL) Exelixis Presents Positive Drug Trial Data</title>
		<link>http://www.stockbloghub.com/2010/05/23/exel-exelixis-presents-positive-drug-trial-data/37991</link>
		<comments>http://www.stockbloghub.com/2010/05/23/exel-exelixis-presents-positive-drug-trial-data/37991#comments</comments>
		<pubDate>Sun, 23 May 2010 20:40:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37991</guid>
		<description><![CDATA[Recently, Exelixis Pharma (EXEL) presented positive data from a mid-stage trial of its lead candidate, XL184. The drug, which is being co-developed with Bristol-Myers Squibb (BMY), is currently undergoing multiple clinical studies for several indications. XL184 is being studied in a phase II trial to treat patients with recurrent glioblastoma (GB), the most common form of brain cancer. Exelixis expects to present these data at the annual meeting of American Society of Clinical Oncology, scheduled next month. The trial aims at studying the safety, tolerability and effectiveness of XL184 in two dosages – 175 mg or 125 mg on previously treated GB patients. The patients selected were divided into two categories – those treated with an antiangiogenic agent and others who were not so treated. It was observed that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/23/exel-exelixis-presents-positive-drug-trial-data/37991/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EXEL) Exelixis Pharma First Quarter Report Narrows Loss</title>
		<link>http://www.stockbloghub.com/2010/05/17/exel-exelixis-pharma-first-quarter-report-narrows-loss/37425</link>
		<comments>http://www.stockbloghub.com/2010/05/17/exel-exelixis-pharma-first-quarter-report-narrows-loss/37425#comments</comments>
		<pubDate>Mon, 17 May 2010 22:43:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37425</guid>
		<description><![CDATA[Exelixis Pharma (EXEL) reported a first quarter loss per share of 25 cents, better than a loss of 34 cents in the year-ago period. However Incorporatedluding restructuring expenses of $16.1 million, loss per share came in at 40 cents. The Zacks Consensus Estimate for the period was a loss of 31 cents. Exelixis Pharma does not have any marketed product and earns revenues primarily from contract and licenses. The company reported $42.2 million in revenues, up 67% compared to the first quarter of 2009. The primary reason for the increase was higher revenues from its collaborative agreement with Sanofi-Aventis (SNY). In addition, a $7 million milestone payment from Genentech also contributed to higher revenues. This was partially offset by lower revenues from its collaboration with Bristol-Myers Squibb (BMY). With development ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/exel-exelixis-pharma-first-quarter-report-narrows-loss/37425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

